Naldemedine Market

Naldemedine Market Size, Share & Industry Analysis, By Source (Pharmaceutical Manufacturers (Branded & Generic), Contract Manufacturing Organizations (CMOs), Research-Grade Suppliers.) By End-User (Pharmaceutical Industry, Hospitals & Clinics, Research Institutions) and Forecast, 2025-2035

The Naldemedine market is projected to grow at a CAGR of 7.4% from 2025 to 2035, driven by the increasing use of opioid-based therapies and the resulting rise in opioid-induced constipation (OIC) cases. Naldemedine is a peripherally acting mu-opioid receptor antagonist (PAMORA) that selectively blocks opioid receptors in the gastrointestinal tract without affecting central analgesia, making it highly effective for treating OIC in patients with chronic pain or cancer who are on long-term opioid therapy.

Its ability to restore normal bowel function without compromising pain relief makes it a valuable adjunct to opioid regimens. Naldemedine is marketed under brand names like Symproic and is supported by favorable clinical outcomes and regulatory approvals in key markets. Growing awareness among clinicians, the increasing focus on opioid side effect management, and the shift toward quality-of-life-oriented care are major factors supporting its adoption.

North America dominates the Naldemedine market, driven by high opioid prescription rates, well-established pain management protocols, and early adoption of PAMORAs. Europe follows, supported by regulatory endorsements and rising palliative care applications. The Asia-Pacific region is projected to experience strong growth due to increasing cancer prevalence, expanding access to palliative care, and gradual uptake of opioid treatments in markets like Japan, India, and South Korea.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Naldemedine
  • Key Applications & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Market Value & Revenue Analysis
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Source
    • Pharmaceutical Manufacturers (Branded & Generic)
    • Contract Manufacturing Organizations (CMOs)
    • Research-Grade Suppliers
  • Key End-Use Industries
    • Pharmaceutical Industry.
    • Hospitals & Clinics.
    • Research Institutions.
  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Production & Supply Volume
  • Global Production Capacity & Key Manufacturers
  • Production Process & Technological Developments
  • Raw Material Analysis
  1. Trade Analysis (Import & Export)
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Market Share
  • Company Profiles & Key Developments
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
What is Naldemedine?
Naldemedine is a peripherally acting μ-opioid receptor antagonist (PAMORA) used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain or in those receiving palliative care. It works by blocking the opioid receptors in the gastrointestinal tract without affecting the analgesic effects of opioids in the central nervous system. Administered orally, Naldemedine is typically taken once daily and is designed to restore bowel function without compromising pain management, making it a valuable option for patients on long-term opioid therapy.
What is the market growth of Naldemedine?
The global Naldemedine market is projected to grow at a CAGR of 7.4% between 2025 and 2035, expanding The market is witnessing growth due to the increasing prevalence of chronic pain conditions requiring long-term opioid therapy and the rising awareness of opioid-induced side effects like constipation. Regulatory approvals across multiple regions and inclusion in clinical guidelines are further driving its market penetration.
What are the drivers of the Naldemedine market?
Key drivers of the Naldemedine market include the global increase in chronic pain conditions such as musculoskeletal disorders, cancer, and post-operative pain, all of which often necessitate opioid use.
Who are the key players operating in the Naldemedine market?
The major player in the Naldemedine market is Shionogi & Co., Ltd., the original developer and marketer of the drug under the brand name Symproic in the U.S., in collaboration with Purdue Pharma and later BioDelivery Sciences International.
Which region will exhibit the fastest growth in the Naldemedine market?
The Asia-Pacific region is expected to witness the fastest growth in the Naldemedine market, driven by the rising use of opioids in pain management, growing elderly populations, and improving access to supportive medications.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.